Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

Researchers compared the polymer-nanoparticle hydrogel system and standard routes of delivery of broadly neutralizing antibodies against SARS-CoV-2 in a mouse model.

27 May 2022

Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study

A new paper presents the results of a mouse study using the repurposed antibacterial drug clofoctol against this virus.

23 May 2022

Insight into sustained-release drug delivery systems

In this interview, News-Medical speaks to Thanh T. Nguyen, a project manager at Innocore Pharmaceuticals, about the mechanisms behind long-acting injectables.

From Thermo Fisher Scientific – Materials & Structural Analysis 18 May 2022

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

A new study published in Marine Drugs evaluated the inhibitory effect of three polysaccharides, crude polysaccharide from Hizikia fusiforme (CPHF), crude polysaccharide from Sargassum horneri (CPSH), and crude polysaccharide from abalone viscera (CPAV) on the propagation of SARS-CoV-2 in vitro.

28 Apr 2022

Novel plug-and-play multi-organ chip can be customized to the patient

Engineered tissues have become a critical component for modeling diseases and testing the efficacy and safety of drugs in a human context.

27 Apr 2022

Study examines how race and sex influence tacrolimus pharmacokinetics in kidney transplant recipients

Kidney transplant survival is shorter, on average, in Black recipients compared to white recipients receiving similar treatment.

18 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -; ATR inhibitor elimusertib and PARP inhibitor AZD5305 -; are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

Study explores phytochemical-based antivirals against SARS-CoV-2 infection

A new study depicted plant-based biologically active antiviral agents that are effective against SARS-CoV-2 infection.

11 Apr 2022

Nanomedicine for treating life-threatening brain tumors

Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka) has announced that Dr. Sabina Quader et al. published a review article focusing on the recent nanomedicines for brain cancers on Advanced Drug Delivery Review in this March.

8 Apr 2022

NYU Langone joins NIH-sponsored program as leading center to discover new targets for autoimmune, inflammatory diseases

NYU Langone Health is joining a new National Institutes of Health (NIH)-sponsored program called Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) as a leading center to discover new targets for therapy in these diseases.

30 Mar 2022

Researchers win NIH grant to treat human brain cancer with a drug previously used on canines

The National Institutes of Health is awarding a $3.8 million grant to John Rossmeisl, the Dr. and Mrs. Dorsey Taylor Mahin Professor of Neurology and Neurosurgery at the Virginia-Maryland College of Veterinary Medicine, and Waldemar Debinski, cancer biology professor at the Wake Forest School of Medicine.

21 Mar 2022

Study results in three new co-amorphous drug systems with great anti-COVID-19 potential

Researchers demonstrated that the bioavailability of matrine-type alkaloids could be prolonged by employing a co-former, resveratrol.

15 Mar 2022

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in Phase I clinical trial evaluating ISM001-055, the first anti-fibrotic small molecule inhibitor generated by Insilico's AI-powered drug discovery platform for idiopathic pulmonary fibrosis (IPF).

24 Feb 2022

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

In a new study, researchers evaluated the efficacy and safety of nirmatrelvir in mild to moderate COVID-19 patients who were at high risk of severe COVID-19 disease.

18 Feb 2022

Trial of early antiviral therapy for COVID-19 shows no significant benefit

A new preprint research paper examines the efficacy of using three antivirals in various combinations in early infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Feb 2022

Phase one study of oral SARS-CoV-2 antiviral agent nirmatrelvir

A recent study posted to the medRxiv* preprint server reported the phase one pharmacokinetic and safety data of nirmatrelvir/ritonavir to facilitate its rapid progression to the last stages of clinical trials in coronavirus disease 2019 (COVID-19) patients with mild to moderate disease.

14 Feb 2022

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Researchers studied the preclinical PK) and in vitro ADME properties of GS-441524, a potential oral drug for COVID-19 treatment.

10 Feb 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

AI systems may one day assist anesthesiologists in the operating room, study suggests

A new study by researchers at MIT and Massachusetts General Hospital suggests the day may be approaching when advanced artificial intelligence systems could assist anesthesiologists in the operating room.

6 Feb 2022

Nanomedicine can be improved with proper and more predictive in vitro assays

Messenger RNA (mRNA) vaccines are a prime example of the promising field of nanomedicine. But progress in the design and application of nanoparticles as efficient delivery vehicles for biopharmaceutics containing nucleic acid or protein drug substances is, unfortunately, remarkably slow.

1 Feb 2022